- Home
- CSBR vs BRNS Comparison
CSBR vs BRNS Comparison
Compare CSBR & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- BRNS
- Stock Information
- Founded
- CSBR 1985
- BRNS 2016
- Country
- CSBR United States
- BRNS United Kingdom
- Employees
- CSBR N/A
- BRNS N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- CSBR Health Care
- BRNS Health Care
- Exchange
- CSBR Nasdaq
- BRNS Nasdaq
- Market Cap
- CSBR 60.6M
- BRNS 52.0M
- IPO Year
- CSBR 1986
- BRNS 2021
- Fundamental
- Price
- CSBR $5.23
- BRNS $1.25
- Analyst Decision
- CSBR Strong Buy
- BRNS Strong Buy
- Analyst Count
- CSBR 2
- BRNS 2
- Target Price
- CSBR $6.75
- BRNS $4.00
- AVG Volume (30 Days)
- CSBR 129.1K
- BRNS 23.1K
- Earning Date
- CSBR 09-11-2024
- BRNS 08-08-2024
- Dividend Yield
- CSBR N/A
- BRNS N/A
- EPS Growth
- CSBR N/A
- BRNS N/A
- EPS
- CSBR N/A
- BRNS N/A
- Revenue
- CSBR $51,655,000.00
- BRNS N/A
- Revenue This Year
- CSBR $9.14
- BRNS $27.18
- Revenue Next Year
- CSBR $10.03
- BRNS N/A
- P/E Ratio
- CSBR N/A
- BRNS N/A
- Revenue Growth
- CSBR N/A
- BRNS N/A
- 52 Week Low
- CSBR $3.60
- BRNS $1.11
- 52 Week High
- CSBR $7.13
- BRNS $5.10
- Technical
- Relative Strength Index (RSI)
- CSBR 67.10
- BRNS 45.47
- Support Level
- CSBR $3.60
- BRNS $1.11
- Resistance Level
- CSBR $5.23
- BRNS $1.31
- Average True Range (ATR)
- CSBR 0.35
- BRNS 0.09
- MACD
- CSBR 0.10
- BRNS 0.01
- Stochastic Oscillator
- CSBR 87.57
- BRNS 48.48
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. They derive revenue primarily from research services.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.